HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of sorafenib combined with
hepatic arterial infusion chemotherapy (HAIC) compared with lenvatinib combined with HAIC in
patients with advanced hepatocellular carcinoma (HCC)